Designs for Mechanical Circulatory Support Device Studies

Journal of Cardiac Failure

Volumn 13, Issue 1, 2007, Pages 63-74

  Neaton, James D ^a   Normand, Sharon Lise ^b   Gelijns, Annetine ^c   Starling, Randall C ^d   Mann, Douglas L ^e   Konstam, Marvin A ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

Control groups; Devices; Study design

Indexed keywords

ARTICLE; CLINICAL STUDY; DEVICE THERAPY; HEALTH CARE MANAGEMENT; HEALTH STATUS; HEART ASSIST DEVICE; HEART GRAFT; HUMAN; IMPLANTATION; MEDICAL INSTRUMENTATION; METHODOLOGY; PRIORITY JOURNAL; SAFETY;

EQUIPMENT DESIGN; HEART FAILURE, CONGESTIVE; HEART-ASSIST DEVICES; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 33847284893     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.12.003     Document Type: Article

References (59)

1. Rosamond W., Glegal K., Friday G., et al. Heart disease and stroke statistics-2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Committee. Circulation 115 (2007) e69-e171
2. Barr M.L., Bourge R.C., Orens J.B., et al. Thoracic organ transplantation in the United States, 1994-2003. Am J Transplant 5 (2005) 934-949
3. 2005 Organ Procurement and Transplantation Network (OPTN)/Scientific Registry of Transplant Recipients (SRTR) Annual Report. Available from: http://www.ustranplant.org/annual_reports/. Accessed February 8, 2007.
4. Deng M.C., Edwards L.B., Hertz M.I., et al. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: Third annual report-2005. J Heart Lung Transplant 24 (2005) 1182-1187
5. Frazier O.H., Rose E.A., Macmanus Q., et al. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. Ann Thorac Surg 53 (1992) 1080-1090
6. Frazier O.H., Rose E.A., McCarthy P., et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg 3 (1995) 327-338
7. Frazier O.H., Rose E.A., Oz M.C., et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 122 (2001) 1186-1195
8. Copeland J.G., Smith R.G., Arabia F.A., et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 351 (2004) 859-867
9. Stevenson L.W., and Kormos R.L. Consensus conference report. Mechanical cardiac support 2000: current applications and future trial design. JACC 37 (2001) 340-370
10. US Food and Drug Administration. Summary minutes: Meeting of the Circulatory System Devices Advisory Panel. Available from: http://www.fda.gov/ohrms/dockets/ac/04/minutes/4029m1_summary.htm. Accessed January 30, 2007.
11. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443
12. Park S.J., Tactor A., Piccioni W., et al. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg 129 (2005) 9-17
13. ® left ventricular assist device in non-transplant candidates: results of the INTrEPID trial [abstract 1960]. American Heart Association, 2005. Available from: http://www.abstractsonline.com/arch/RecordView.aspx?LookupKey=12345&recordID=20821. Accessed February 8, 2007.
14. World Heart. Clinical trials. Available from: http://www.worldheart.com/clinical_information/clinical_trials.cfm. Accessed January 30, 2007.
15. Mancini D., and Burkhoff D. Mechanical device-based methods of managing and treating heart failure. Circulation 112 (2005) 438-448
16. Konstam M.A., Piña I., Linefeed J., and Packer M. A device is not a drug. J Cardiac Failure 9 (2003) 155-157
17. Rose E.A., Moskowitz A.J., Packer M., et al. The REMATCH Trial: rationale, design, and end points. Ann Thorac Surg 67 (1999) 723-730
18. Friedman L.M., Furberg C.D., and DeMets D.L. Fundamentals of clinical trial (1998), Springer-Verlag, New York (NY)
19. Schulz K.F. Subverting randomization in controlled trials. JAMA 274 (1995) 1456-1458
20. Hill A.B. The clinical trial. Br Med Bull 7 (1951) 278-282
21. Fisher R.A. The arrangement of field experiments. J Ministry Agric Great Br 33 (1926) 503-513
22. Armitage P. The role of randomization in clinical trials. Stat Med 1 (1982) 345-352
23. MacMahon S., and Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II. Observational studies. Lancet 357 (2001) 455-462
24. Temple R., and Ellenberg S.S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Ann Intern Med 133 (2000) 455-470
25. Pocock S.J. The pros and cons of noninferiority trials. Fund Clin Pharmacol 17 (2003) 483-490
26. Simon R. Bayesian design and analysis of active controlled clinical trials. Biometrics 55 (1999) 484-487
27. Levy W.C., Mozaffarian D., Linker D.T., et al. The Seattle Heart Failure Model. Prediction of survival in heart failure. Circulation 113 (2006) 1424-1433
28. Baumgartner WA, Burrows S, del Nido P, et al. Recommendations of the National Heart, Lung, and Blood Institute Working Group on Future Direction in Cardiac Surgery. Circulation 111:3007-13.
29. Byar D.M. Design considerations for AIDS trial. J Acquire Immune Defic Syndr 2 Suppl (1990) S16-S19
30. Baim D.S., McDowell A.V., Cherniles J., et al. Evaluation of a new bipyridine inotropic agent-milrinone-in patients with severe congestive heart failure. N Engl J Med 309 (1983) 748-756
31. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325 (1991) 1468-1475
32. Meinert C.L. Clinical trials dictionary (1996), Johns Hopkins Center for Clinical Trials, Baltimore (MD)
33. Byar D. Why data bases should not replace randomized clinical trials. Biometrics 36 (1980) 337-342
34. Byar D., Simon R., Friedewald W.T., et al. Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med 8 (1976) 74-80
35. Personal communication, James Kirklin, MD, Principal Investigator, INTERMACS, October 2006.
36. Rosenbaum P., and Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 70 (1983) 41-55
37. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 (1997) 757-763
38. Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to non-randomized medical device clinical studies. J Bio Pharm Stat. 2007;17:1-13.
39. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34 (1976) 585-612
40. Pocock S.J. The combination of randomized and historical controls in clinical trials. J Chron Dis 29 (1976) 175-188
41. Machin D. On the possibility of incorporating patients from non-randomising centres into a randomized trial. J Chron Dis 32 (1979) 347-353
42. Marcus S.M. Assessing non-consent bias with parallel randomized and nonrandomized clinical trials. J Clin Epidemiol 50 (1997) 823-828
43. Olschewski M., Schumacher M., and Davis K.B. Analysis of randomized and non-randomized patients in clinical trials using the comprehensive cohort-follow-up study design. Cont Clin Trials 13 (1992) 226-239
44. Schumacher M., and Davis K. Combining randomized and nonrandomized patients in the statistical analysis of clinical trials. Recent results in cancer research Vol. III (1988), Springer-Verlag, Berlin
45. Prentice R.L., Langer R.D., Stefanick M.L., et al. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 163 (2006) 589-599
46. Parides M.K., Moskowitz A.J., Ascheim D.D., Rose E.A., and Gelijns A.C. Progress versus precision: challenges in clinical trial design for left ventricular assist devices. Ann Thor Surg 82 (2006) 1140-1146
47. Black H.R., Elliott W.J., Grandits G., et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. JAMA 289 (2003) 2073-2082
48. MacArthur R.D., Chen L., Mayers D.L., et al. The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial. Control Clin Trials 22 (2001) 176-190
49. Schmoor C., Olschewski M., and Schumacher M. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. Stat Med 15 (1996) 263-271
50. Rimm E.B., Stampfer M.J., Ascherio A., et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328 (1993) 1450-1456
51. Stampfer M.J., Hennekens C.H., Manson J.E., et al. Vitamin E consumption and the risk of coronary heart disease in women. N Engl J Med 328 (1993) 1444-1449
52. The Alpha-Tocopherol Beta Carotene cancer prevention study group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other causes in male smokers. N Engl J Med 330 (1994) 1029-1035
53. Khaw K.T., Bingham S., Welch A., et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet 357 (2001) 657-663
54. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 23-33
55. Stampfer M., and Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 20 (1991) 47-63
56. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results of the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
57. Chalmers T.C. Letters to the Editor. When should randomization begin?. Lancet 1 (1968) 858
58. Hak E., Verheij Th J.M., Grobbee D.E., Nichol K.L., and Hoes A.W. Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Commun Health 56 (2006) 951-955
59. Hill A.B. Medical ethics and controlled trials. BMJ i (1963) 1043-1049